Our Team


Leadership

Daniel Baldoni, MD - CEO & Head of Regulatory

Daniel is the founder and CEO of Baldoni Neuromodulation. He received his B.S. in Physics with Honors, and an M.D. from Geisinger Commonwealth School of Medicine. His initial interest in neuromodulation began during undergraduate training and led him to concentrate on neuroscience, neurosurgery, and adult/pediatric neurology during medical training. Following medical school, he worked in the Advanced Technology team at Nevro where his job was to come up with neuromodulation commercial innovations to feed Nevro’s product pipeline. He has a track record of commercial success for noninvasive neuro devices including a commercialized tremor device and acupressure clip. After writing the bulk of the class III Deep Brain Stimulation investigational device exception (IDE) regulatory package for Nevro, Daniel started to become more interested in noninvasive device development. He decided to leave Nevro with his wife Emily and move to Austin and start Baldoni Neuromodulation. After developing a variety of contract projects, he was able to make progress on his own special interest in combining high-frequency electrical current and ultrasound hyperthermia for the treatment of glioblastoma, a disease with devastating consequences and limited treatment options. His goal is to make an impact on the disease through commercialization of a combination device that will improve survival.

Yusuf Tufail, PhD - Head of Technology and Preclinical

Yusuf is a Senior Research Scientist at the Lundbeck La Jolla Research Center and formerly Project Scientist at the Salk Institute in La Jolla, CA. He has an extensive background in ultrasonic neuromodulation and ultrasonic technology development. He is a highly motivated and team-oriented neuroscientist with a background in neuro-glia biology and experience with discovering novel proof-of- concept therapies for synaptic, neuroinflammatory and neurodegenerative diseases. He is dedicated to hypothesis driven research projects aimed at discovering therapies to correct dysfunctions of the Central Nervous System. He has been discussing the proposed project for some time with Daniel and looks forward to continue contributing to move this development forward. His expertise in ultrasound design and engineering will be integral in preclinical and clinical application.

Jordan Amadio, MD - Head of Clinical

Jordan's background includes receiving an A.B. in biophysics from Princeton University, an M.D. from Harvard Medical School, and completing a neurosurgical residency at Emory University School of Medicine. His publications range from basic neuroscience to clinical neurosurgery and includes a neurogenetics brain evolution paper published in Cell, an atypical pituitary adenoma clinical case published in the Journal of Neurosurgery, and emerging deep brain stimulation techniques and related ethics papers published in AMA Journal of Ethics and AJOB Neuroscience. As a neurosurgeon at UT Dell Seton Medical Center and affiliate faculty member at the University of Texas Dell Medical School, he frequently cares for patients with intracranial tumors including glioblastoma. He previously founded a neurotechnology startup accelerator, NeuroLaunch, and believes neurotechnology has potential to be transformative in medicine. More recently, he became a co-investigator with Dr. Farshid Alambeigi, Ph.D. to develop advanced steerable surgical robots and flexible implants through an NIH R21 funded award and am an advisor for a neuromodulation startup treating sleep apnea. He has experience with MR thermometry that could be involved in the clinical translation of the described glioblastoma device. He believes alternating current therapy is a promising new addition to the standard-of-care for patients with glioblastoma and an ultrasound hyperthermia combination approach would be a practical way to potentially further improve its efficacy. He has seen various prototype iterations for this and other devices in development over the past few years and is keenly interested in quickly translating this technology to the clinic.

John Baldoni, PhD - Executive Advisor

 John has 41 years of experience in the pharmaceutical industry with 29 years at GlaxoSmithKline (GSK) in Research and Development and 11 years on its Executive Leadership Team. He continues to serve on non-Executive Boards, Scientific Advisory Boards and consultantships for several healthcare companies. He has participated in the research and development of more than 50 commercial products and is a proponent of seeking, integrating, and implementing innovative approaches to therapeutic discovery and development. He led several GSK platform innovation initiatives through internal teams, and technology acquisition and partnerships. He conceptualized and was senior science advisor of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, an open membership, public/private partnership currently comprised of GSK, Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. He was the former Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention and innovation in artificial intelligence. He looks forward to serving as advisor by offering insight from commercialization, technology, and regulatory perspectives.